In addition to the RSV collaboration, the biopharmaceutical firm is working with the institute on the clinical development of HIV and influenza vaccines.
“Data emerging from the clinical trials of our HIV vaccine candidate indicates that GenVec’s adenovector technology induces both antibodies and cellular immune responses,” said Rick King, GenVec’s senior vice president of research.